Eptifibatide
Also known as: ABT-527, Integrelin, Integrilin, L-734217
Source Eptifibatide at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Eptifibatide is a synthetic cyclic heptapeptide that inhibits platelet aggregation via GPIIb/IIIa blockade; administered intravenously to prevent thrombotic complications in acute coronary syndrome and during percutaneous coronary interventions.
Mechanism of Action
Reversible antagonist of platelet glycoprotein IIb/IIIa (integrin αIIbβ3), blocking fibrinogen binding and platelet aggregation
Routes of Administration
Goals & Uses
- Adjunct to percutaneous coronary interventionInterventional CardiologyHigh
- Prevention of abrupt vessel closure post-PCICardiovascular / Thrombosis PreventionHigh
- Prevention of acute coronary thrombosisCardiovascularHigh
- Percutaneous Coronary Intervention (PCI) adjunctCardiovascular / AntiplateletHigh
- Acute Coronary Syndrome (ACS) managementCardiovascular / AntiplateletHigh
Contraindications
- Thrombocytopenia (<100,000/µL)HematologicModerate
- Thrombocytopenia (platelet count <100,000/mm³)HematologicalHigh
- Major surgery or trauma within 6 weeksSurgicalHigh
- Recent intracranial hemorrhage (≤30 days)NeurologicHigh
- Severe renal impairment (creatinine ≥4 mg/dL or dialysis dependency)RenalHigh
- Active pathological bleedingBleeding RiskHigh
- Known hypersensitivity to eptifibatide or any component of the formulationAllergyModerate
- History of stroke within 30 days or hemorrhagic stroke at any timeNeurologicalHigh
- Active internal bleeding or bleeding diathesis within 30 daysBleeding RiskHigh
- Severe uncontrolled hypertension (SBP >180 mmHg or DBP >110 mmHg)CardiovascularModerate
- Severe hypertension (uncontrolled, systolic >200 mmHg or diastolic >110 mmHg)CardiovascularHigh
Adverse Effects
- ThrombocytopeniaHematologicUncommonLow platelet count
- HeadacheNeurologicCommonPain in the head or upper neck
- HypotensionCardiovascularUncommonLow blood pressure
- NauseaGastrointestinalCommonFeeling of sickness or urge to vomit
- Allergic/hypersensitivity reactionsImmunologicalRare
- BleedingHematologicCommonAbnormal bleeding or hemorrhage
- Bleeding (minor and major)HemorrhagicCommon
Drug Interactions
- HeparinHigh
- Heparin / Low-molecular-weight heparinsModerate
- Thienopyridines (clopidogrel, ticagrelor)Moderate
- WarfarinHigh
- Aspirin / NSAIDsModerate
- Other GPIIb/IIIa inhibitors (abciximab, tirofiban)High
- Other GP IIb/IIIa inhibitors (e.g., abciximab, tirofiban)High
- Warfarin / oral anticoagulantsHigh
- Clopidogrel or other ADP‑P2Y12 inhibitorsModerate
Population Constraints
- PregnancyReproductive SafetyRelative
- Renal impairment (moderate: CrCl <50 mL/min)RenalRelative
- Low body weight patients (<60 kg)AnthropometricRelative
- Pediatric patientsAgeRelative
- Elderly patients (≥75 years)AgeRelative
- Elderly (≥75 years)AgeRelative
Regulatory Status
- European UnionApprovedApproved: Acute coronary syndrome, PCIApproved in EU member states; same brand name
- United StatesApprovedApproved: Unstable angina, NSTEMI, Adjunct to PCIApproved under prescription; marketed as Integrilin
- United KingdomApprovedApproved: Acute coronary syndrome, PCIApproved by MHRA; prescription only
FDA approved in 1998 (brand Integrilin); also approved in the EU and UK for acute coronary syndrome and PCI.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Eptifibatide?
Eptifibatide is a synthetic cyclic heptapeptide that inhibits platelet aggregation via GPIIb/IIIa blockade; administered intravenously to prevent thrombotic complications in acute coronary syndrome and during percutaneous coronary interventions.
What is Eptifibatide used for?
Eptifibatide is educationally associated with: Adjunct to percutaneous coronary intervention, Prevention of abrupt vessel closure post-PCI, Prevention of acute coronary thrombosis, Percutaneous Coronary Intervention (PCI) adjunct, Acute Coronary Syndrome (ACS) management. Educational only — not medical advice.
How is Eptifibatide administered?
Recorded routes of administration: Intravenous.
What are the potential side effects of Eptifibatide?
Reported adverse effects include: Thrombocytopenia, Headache, Hypotension, Nausea, Allergic/hypersensitivity reactions, Bleeding, Bleeding (minor and major). This list is not exhaustive — consult a qualified clinician.
Who should avoid Eptifibatide?
Recorded contraindications: Thrombocytopenia (<100,000/µL), Thrombocytopenia (platelet count <100,000/mm³), Major surgery or trauma within 6 weeks, Recent intracranial hemorrhage (≤30 days), Severe renal impairment (creatinine ≥4 mg/dL or dialysis dependency), Active pathological bleeding, Known hypersensitivity to eptifibatide or any component of the formulation, History of stroke within 30 days or hemorrhagic stroke at any time, Active internal bleeding or bleeding diathesis within 30 days, Severe uncontrolled hypertension (SBP >180 mmHg or DBP >110 mmHg), Severe hypertension (uncontrolled, systolic >200 mmHg or diastolic >110 mmHg). Consult a qualified clinician before use.